UNSPSC 51162621: Dipropizine or dropropizine

This classification denotes an antispasmotic agent with the molecular formula C13H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U0K8WHL37U, chemically known as 1,2-propanediol, 3-(4-phenyl-1-piperazinyl)-, (r,s)- but more generally known as dropropizine, which bears US NIH Compound Identifier 3169. European Medicines Agency schedules Dropropizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06412MIG.

UNSPSC 51162621 Dipropizine or dropropizine is a Commodity code that in recent state and local activity captures procurement of naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products for distribution across public health and government facilities. State and local governments soliciting under this code include county health departments, state procurement offices administering cooperative purchasing agreements, and multistate purchasing alliances. Work being procured ranges from single-jurisdiction buys of naloxone and drug deactivation kits to large-scale multi-state cooperative pharmaceutical supply contracts serving hundreds of participating government entities across multiple states.

Recent activity spans Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, responses due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with responses due March 26, 2026; the contract was to be effective July 1, 2026, with evaluation weighted heavily toward price competitiveness (75 percent) and compliance with cGMP and Drug Supply Chain Security Act requirements. Both procurements require vendor compliance with E-Verify, workers' compensation and commercial general liability insurance, FDA standards, and demonstrated ability to meet delivery schedules and product specifications using designated electronic procurement systems.